Humphrey O. Atiemo, MD Glickman Urological Institute, Cleveland Clinic
Louis Moy, MD University of Pennsylvania, Philadelphia
Sandip Vasavada, MD Glickman Urological Institute, Cleveland Clinic,
Raymond Rackley, MD Glickman Urological Institute, Cleveland Clinic
Address: Raymond Rackley, MD, Glickman Urological Institute, A100, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rackler@ccf.org
Dr. Atiemo has indicated that he is on the speaker's bureau of the Pfizer corporation.
Dr. Vasavada has indicated that he serves as a consultant or on the speaker's bureaus of the Novartis and Pfizer corporations and owns stock in the Neurostim Design and Innovation Medical corporation.
Dr. Rackley has indicated that he has received grant or research support from the Allergan and Novartis corporations and the Interstitial Cystitis Association; serves as a consultant or on the speaker's bureau of the Allergan, American Medical Systems, Astellas, Boston Scientific, Novartis, and Pfizer corporations; and owns stock in the Neurostim Design and Innovation Medical corporation.
ABSTRACTMen who become persistently incontinent after undergoing prostatectomy have a variety of options for regaining control, ranging from behavioral changes to surgery. To determine the best therapy, one should define the problem with a thorough urologic evaluation.
